A Comparative Study of an Integrated Pharmaceutical Care Plan and a Routine Care in Bronchial Asthma
Overview
The aim of the study is to compare the effect of asthma care by clinical pharmacist intervention versus routine care on asthma control.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Health Services Research
- Masking: None (Open Label)
- Study Primary Completion Date: January 2013
Interventions
- Other: Pharmacist- Intervention
- Patients received additional education on basic facts about asthma, role of medications, the difference between long-term control medications and quick-relief medications, as well as patient skills in the first visit then reinforcement every two weeks.. The importance of proper inhaler technique, avoidance of asthma triggers and self-monitoring of asthma were also highlighted. Visual aids, physical demonstration as well as written information resources were supplied. Asthma care plans were tailored to patient needs and preferences. Patients were informed how to detect early signs of worsening asthma, when and how to seek medical care as appropriate.
- Other: Routine Care
- Patients received usual care delivered by physician without pharmacist intervention. Patients were prescribed asthma medication with summarized basic information on asthma and medication use. Follow-up visits were not planned on consistent basis, but rather individually according to the disease status. No asthma action plans were provided.
Arms, Groups and Cohorts
- Experimental: Pharmacist-Intervention
- Active Comparator: Routine Care
Clinical Trial Outcome Measures
Primary Measures
- Asthma Control Questionnaire
- Time Frame: at baseline & after 2 months of therapy
Secondary Measures
- Forced Expiratory Volume in 1 second (FEV1%)
- Time Frame: at baseline & after 2 months of therapy
- Rescue Medication SABA (number of puffs used most days)
- Time Frame: at baseline & after 2 months of therapy
- Inhaled Corticosteroid Use (number of puffs used/day)
- Time Frame: at baseline & after 2 months of therapy
- Number of courses of systemic steroid used
- Time Frame: During 2 months of therapy
- Number of ER visits/ Hospitalization
- Time Frame: During 2 months of therapy
Participating in This Clinical Trial
Inclusion Criteria
- patient with clinical diagnosis of bronchial asthma – responsible for administering their own asthma medications. Exclusion Criteria:
- patients who were not responsible for administering their own asthma medications. – patients with cognitive defects, other pulmonary disease e.g. Chronic Obstructive Pulmonary Disease (COPD), experiencing illness with asthma-like symptoms e.g. Congestive Heart Failure, evidence of fixed airway obstruction – patients unavailable for 2-month follow-up. – patients who did not provide written informed consent.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 70 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Ain Shams University
- Provider of Information About this Clinical Study
- Principal Investigator: Rana Rasheed Ibrahim Farrag, Pharmacist – Ain Shams University
- Overall Official(s)
- Rana R Farrag, Principal Investigator, Ahram Canadian University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.